Irbesartan

동의어: Irbesartan, 138402-11-6, SR 47436, BMS-186295, Avapro, Aprovel, Karvea, Irbesartanum

Irbesartan is a non-peptide angiotensin II receptor antagonist with a biphenyl-tetrazole scaffold that selectively blocks the AT1 receptor subtype. Its molecular structure features an imidazolinone ring linked to a biphenyl moiety, a configuration that yields high affinity for the AT1 receptor and a long duration of action. Unlike ACE inhibitors, irbesartan does not inhibit the breakdown of bradykinin, which translates to a lower incidence of dry cough in clinical use.

Developed by Sanofi and Bristol-Myers Squibb, irbesartan was approved in 1997 for the treatment of hypertension and later for diabetic nephropathy in patients with type 2 diabetes. Today, it is widely available as a generic active pharmaceutical ingredient (API), and its patent expiration has made it a staple in cardiovascular therapy worldwide.

In the pharmaceutical industry, irbesartan is used to manufacture oral solid dosage forms, typically tablets containing 75 mg, 150 mg, or 300 mg. It is also a reference compound in analytical research and a key intermediate in the synthesis of related sartans.

Chemical Structure & Properties

Irbesartan belongs to the class of biphenyl-2-tetrazolyl compounds. The molecule contains a tetrazole ring that mimics the carboxylate group of angiotensin II, a biphenyl core for lipophilic interactions, and an imidazolinone ring that contributes to receptor binding. It appears as a white to off-white crystalline powder, is slightly soluble in methanol, and practically insoluble in water. Its molecular weight is 428.53 g/mol, and it exhibits polymorphism, with Form A being the most thermodynamically stable and commonly used in pharmaceutical formulations.

작용 기전

• AT1 receptor blockade: Irbesartan selectively antagonizes the angiotensin II type 1 (AT1) receptor, preventing the vasoconstrictive and aldosterone-secreting effects of angiotensin II.
• Blood pressure reduction: By blocking AT1 receptors, it lowers peripheral vascular resistance and reduces blood pressure without affecting heart rate.
• Renal protection: It decreases intraglomerular pressure and proteinuria, making it beneficial in diabetic nephropathy.
• No bradykinin accumulation: Unlike ACE inhibitors, it does not inhibit kininase II, resulting in a lower risk of cough and angioedema.

Quality Specifications (QC Tests)

Supply & Documentation

• Capacity: 50 metric tons per year
• 리드 타임: 3-5 business days (stock items)
• 문서: COA, MSDS, TDS, DMF available upon request
• 포장: 25 kg fiber drum with double polyethylene liner, or as per customer requirements

자주 묻는 질문

What is the minimum order quantity (MOQ) for Irbesartan?

Our standard MOQ is 25 kg, but we can accommodate smaller quantities for trial orders. Please contact us for specific requirements.

What is the typical lead time for delivery?

For standard orders, lead time is 3-5 business days after order confirmation. For customized packaging or documentation, it may be slightly longer.

Do you provide a Certificate of Analysis (COA) and samples?

Yes, we provide a COA for each batch and can supply samples for quality evaluation. Please request a sample through our sales team.

Contact & Ordering Information

• Company: LyvBio Co., Ltd.
• Address: Room 5-0203, Courtyard 205, Lianhu District, Xi’an, Shaanxi, China
• Email: info@lyvbio.com
• Phone: +86-29-65816888

Learn more about our quality control and certifications, or send us your specification for a quotation.